Mr. Speaker, last week, drug manufacturer sanofi-aventis announced that it was laying off 70 workers. The company lamented the fact that the federal government provides inadequate support for innovative companies' research activities. It also noted that, unlike generic drug companies, innovative companies have no meaningful right of appeal when their intellectual property is challenged.
When will the minister provide the kind of balanced intellectual property protection that is critical to Quebec's economic development?